bio.logis held its inaugural Scientific Advisory Board (SAB) meeting in Frankfurt.
Scientific Advisory Board supports bio.logis plans for medically sound and ethically responsible personal genomics service (PGS)
bio.logis held its inaugural Scientific Advisory Board (SAB) meeting in Frankfurt.
A key objective of the meeting was to solicit feedback on the development of bio.logis’ innovative personal genomics services (PGS). bio.logis today supports physicians with high-quality genetic information for diagnosis and treatment. With PGS bio.logis aims to bring the benefits of genetic information directly to customers.
‘As more and more information becomes available about the genetic basis of disease susceptibility, understanding our personal genetic make-up will play a key role in maintaining and improving our health and well-being’ states Professor Anthony Monaco, member of bio.logis’ SAB. ‘I am excited to see bio.logis introducing a medically sound and ethically responsible approach that will enable customers to use this information today and in the future in a safe manner.’
Professor Daniela Steinberger, founder and Medical Director of bio.logis, is impressed by the commitment of the SAB members and the very constructive feedback. ‘We are proud of our scientific advisory board with very seasoned and highly regarded researchers and thought-leaders in human genetics. We value their independent opinion as we shape bio.logis and our service offerings.’
Professor Ivar Roots, member of the SAB, emphasizes the importance of the pharmacogenetic markers that are part of the PGS offering. ‘Pharmacogenetic biomarkers are a key enabler of personalized medicine. While this field is under continued rapid development, there is already today a broad set of validated targets that can be assessed to avoid severe side effects of common prescription drugs. I strongly support the bio.logis approach of making this scientifically sound knowledge available as a step towards making drug therapy safer for everyone.’
About the Scientific Advisory Board of bio.logis
Professor Anthony P. Monaco is regarded as one of the scientific leaders in human genetics. He is a pioneer in the area of positional cloning of disease genes and of the genetic analysis of multifactorial (complex) disorders. Professor Monaco has characterized numerous genes associated with both monogenic and complex inherited disorders. He has been honored for his groundbreaking research in the field of human genetics with much international praise and awards. From 1998-2007, he was director of the Wellcome Trust Centre for Human Genetics at the University of Oxford, the first and one of the leading research institutes for the analysis of multifactorial genetic disorders and susceptibility variants. In October 2007 he was appointed Pro-Vice-Chancellor at the University of Oxford Professor Ulrich Müller has written over 250 original research and review articles on all aspects of Human Genetics and is one of the most renown geneticists in Germany. Ulrich Müller has obtained his MD and “Habilitation” (PhD equivalent) at the university of Freiburg/Germany. On a Heisenberg fellowship he was a visiting scientist at Children's Hospital of Harvard Medical School in Boston, where he became an assistant and associate professor in pediatrics/genetics. Ulrich Müller has been director of the Institute of Human Genetics at the Justus-Liebig-University of Gießen since 1992. He is a founding member of the German Society of Neurogenetics and was the President of this society from 1994-2004. Professor Müller is a member of the editorial board of numerous scientific journals and is cofounder and -editor of the international scientific periodical Neurogenetics.
Professor Roots has been director of the Institute of Clinical Pharmacology at the Charité Medical School of Humboldt University at Berlin since 1993. As of 2006 he has also been the director of Charité Center for Research in Therapeutics. Prof. Roots’ area of scientific interest has been pharmacological genetics for more than 20 years with the goal of individualizing drug therapies. Among many publically endorsed research projects, he was first and foremost the initiator and spokesperson for the national research project supported by the Federal Ministry Education and Research "Pharmacogenetic diagnostics - Improvement of therapy and drug development"
(1999-2003).
About bio.logis GmbH
bio.logis was established as an independent startup in 2008. It supplies customers with information about their genetic make-up in a medically and ethically responsible manner enabling informed decision making as to health and lifestyle. For more details please see http://www.biologis.com/.
Contact
Dr. phil. Maike Post
Altenhöferallee 3
60438 Frankfurt am Main
T +49 (0) 69-530 8437-0
E-Mail: maike.post@bio.logis.de